Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepranemab in Prodromal to Mild Alzheimer's Disease
2020-005829-88Phase 2Active
- Sponsor
- UCB
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Bepranemab with Placebo (2 arms). Primary endpoint: Change in CDR-SB total score. Started Apr 2021; status: active.
02
Drugs
Bepranemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-005829-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005829-88.